(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -25.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Cytomx Therapeutics's revenue in 2025 is $147,557,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2025 to be $7,961,836,412, with the lowest CTMX revenue forecast at $5,072,691,756, and the highest CTMX revenue forecast at $11,361,152,610. On average, 5 Wall Street analysts forecast CTMX's revenue for 2026 to be $5,237,965,406, with the lowest CTMX revenue forecast at $322,485,172, and the highest CTMX revenue forecast at $9,674,555,160.
In 2027, CTMX is forecast to generate $6,046,596,975 in revenue, with the lowest revenue forecast at $4,031,145,271 and the highest revenue forecast at $8,062,129,300.